Navigation Links
Contrast agent linked with brain abnormalities on MRI
Date:12/16/2013

OAK BROOK, Ill. For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. The new study raises the possibility that a toxic component of the contrast agent may remain in the body long after administration.

Brain MRI exams are often performed with a gadolinium-based contrast medium (Gd-CM). Gadolinium's paramagnetic properties make it useful for MRI, but the toxicity of the gadolinium ion means it must be chemically bonded with non-metal ions so that it can be carried through the kidneys and out of the body before the ion is released in tissue. Gd-CM is considered safe in patients with normal kidney function.

However, in recent years, clinicians in Japan noticed that patients with a history of multiple administrations of Gd-CM showed areas of high intensity, or hyperintensity, on MRI in two brain regions: the dentate nucleus (DN) and globus pallidus (GP). The precise clinical ramifications of hyperintensity are not known, but hyperintensity in the DN has been associated with multiple sclerosis, while hyperintensity of the GP is linked with hepatic dysfunction and several diseases.

To learn more, the researchers compared unenhanced T1-weighted MR images (T1WI) of 19 patients who had undergone six or more contrast-enhanced brain scans with 16 patients who had received six or fewer unenhanced scans. The hyperintensity of both the DN and the GP correlated with the number of Gd-CM administrations.

"Hyperintensity in the DN and GP on unenhanced MRI may be a consequence of the number of previous Gd-CM administrations," said lead author Tomonori Kanda, M.D., Ph.D., from Teikyo University School of Medicine in Tokyo and the Hyogo Cancer Center in Akashi, Japan. "Because gadolinium has a high signal intensity in the body, our data may suggest that the toxic
'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Research reveals contrasting consequences of a warmer Earth
2. Bees attracted to contrasting colors when looking for nectar
3. First oral agent to quell invasive macular degeneration, restore lost vision
4. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
5. Paints and coatings containing bactericidal agent nanoparticles combat marine fouling
6. Boston subway system to be used to test new sensors for biological agents
7. Project MICREAgents: Self-assembling smart microscopic reagents to pioneer pourable electronics
8. Novel non-antibiotic agents against MRSA and common strep infections
9. Production of FRP components without release agents
10. Developing second skin military fabric to repel chemical and biological agents
11. Preventive detention for oxidizing agents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Contrast agent linked with brain abnormalities on MRI
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... of choice when it comes to the types of fat cells in ... it. The danger in white fat cells, along with the increased risk ... fat. Visceral fat is the build-up of fat around the organs in ... fat appears to be our friend and white fat our foe. ...
... FL (May 6, 2012) There may be new ... medicine injected directly into the eyes fails to cause ... called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle ... with the fast-progressive form of macular degeneration, they are ...
... in German . Halle/Saale. In order to ... These differ in part considerably from the propagation strategies of ... Knapp of the Helmholtz Centre for Environmental Research (UFZ) reached ... of the scientific journal Ecology Letters . "These results ...
Cached Biology News:A new candidate pathway for treating visceral obesity 2First oral agent to quell invasive macular degeneration, restore lost vision 2First oral agent to quell invasive macular degeneration, restore lost vision 3Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... control projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... volume year for bidding in 2014, we are pleased to see ... reflect the organization,s renewed focus on select market segments where we ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... has closed a public offering of three million ... million for general corporate purposes. , ,The company announced ... $3.75 per share, marketed to institutional investors following a ... Exchange Commission . , ,Sonic Foundry, which develops a ...
... , a Grand Rapids-based provider of data bandwidth capacity, will ... in metropolitan Milwaukee. , ,The company, which serves Midwestern enterprise ... 31 of this year. , ,US Signal's network deployment ... Milwaukee and powered by the Cisco optical platform. ...
... Madison, Wis. - Third Wave Technologies, Inc ., ... to the U.S. Food and Drug Administration for approval of ... test product, which Third Wave calls InPlex, is a genotyping ... to aid in newborn screening and in diagnostic testing in ...
Cached Biology Technology:
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: